Synta Pharmaceuticals has entered into a partnership with Roche to discover and develop small molecules that target CRACM channels implicated in various inflammatory diseases. Although this is only the second major agreement signed by Synta, it could prove to be its most rewarding should the partners succeed in developing a drug with disease-modifying attributes against inflammatory conditions.